September 2013 Editor's Picks: Products from AspenTech and Schenck - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

September 2013 Editor's Picks: Products from AspenTech and Schenck

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Aspen Technology
Software enables faster optimization and improved plant safety for manufacturing process.

Aspen Techology’s latest release of its flagship software, aspenONE V8.3, includes new functionality in the Aspen HYSYS process simulation software that allows process engineers to size pressure safety valves (PSV) as an integral part of the overall process design. This feature allows calculation of necessary safety valve sizing specifications, including relief loads and orifice size. Process data can be used to analyze multiple overpressure scenarios, and a documentation-builder tool creates data and summary sheets. Another new feature, silent-install deployment, speeds software deployment.


Schenck AccuRate
A feeder’s disposable feed hopper shortens cleaning time and reduces cross-contamination.


The Schenck AccuRate AP-300 PureFeed feeder is designed for quick and easy disassembly, a dual-arm agitation system for maximizing material handling versatility, and an FDA-compliant feed hopper that is disposable and recyclable. The disposable feed hopper allows shorter cleaning cycles and virtually no chance of cross-contamination when moving from one material to another. The PureFeed AP-300 is available in volumetric and gravimetric configurations for pharmaceutical and nutraceutical applications with feed rates from 0.5 to approximately 150 kg/h.

.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Equipment and Processing Report,
Click here